Our studies define distinct functional subgroups of ccRCCs based on expression of BAF180, and suggest that BAF180 inhibition may be a novel therapeutic target for patients with H2, but not H1H2, ccRCC tumors. This evidence concerns the gene PBRM1 and nonpapillary renal cell carcinoma.